Pharmala Biotech (MDMA) Q3 2025 earnings summary

Executive summary

• Domestic Canadian distribution re-opened, matching last fiscal year's Q2 and Q3 volume in just two quarters.

• Prescriber's Portal launched, strengthening relationships with physician customers.

• Large shipment of LaNeo MDMA delivered to US partner for clinical trial customers.

• Completed manufacturing run in Australia for 40mg LaNeo Capsules, improving global supply and operational efficiency.

Financial highlights

• Customer deposits grew by $150,463 in Q3, with $79,558 in revenue recognized.

• Product revenue recognized: $79,408 for Q3 and $168,289 for the nine months ended June 30, 2025.

• Total expenses for nine months ended May 31, 2025, were $2,117,495, up from $1,085,458 year-over-year.

• Cost of sales for the same period: $19,123 in 2025 vs. $296,962 in 2024.

• Non-cash expenses (bad debt, depreciation, stock-based compensation, loss on debt settlement) totaled $988,811 in 2025 vs. $345,101 in 2024.

Outlook and guidance

• Anticipates further clinical trial fulfillment to US and international customers in the near term.

• Improved manufacturing process expected to yield ongoing operational benefits.